Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET
Company Participants
David Szekeres – Executive Vice President, Chief Operating Officer
Barry Quart – Chief Executive Officer and Chairman
John Poyhonen – President and Chief Commercial Officer
Conference Call Participants
Josh Schimmer – Evercore
Serge Belanger – Needham and Company
Operator
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q2 2022 Earnings Conference. As a reminder, this conference is being recorded.
Now I would like to turn the call over to David Szekeres, Executive Vice President, Chief Operating Officer. Please proceed.
David Szekeres
Good afternoon, everyone, and thank you for joining us. With me today from Heron are Barry Quart, Chief Executive Officer and Chairman; and John Poyhonen, President and Chief Commercial Officer.
For those of you participating via conference call, the slides are made available via webcast and can also be accessed by going to the Investor Relations page of our website, following conclusion of today’s call.
Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Heron’s future expectations, plans, prospects, corporate strategy and performance, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including those discussed in our filings with the SEC.
Any forward-looking statements represent our views only as of the date of this webcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements.
Now, I’ll turn the call over to Barry.
Barry Quart
Thank you, David. Welcome everyone. And thank you for joining us. Second quarter has been extremely productive on a number of fronts. John will discuss details regarding our two commercial franchises, both of which showed good growth in second quarter beating consensus estimates.
During second quarter, we continued to prosecute our NDA for HTX-019 for postoperative nausea and vomiting, which has the potential to be many times larger than our CINV business. Interactions with the FDA remain on track for the September 17th PDUFA date. We've also made excellent progress completing enrollment in the four clinical trials with ZYNRELEF planned for inclusion in what we call sNDA-number two, designed to further expand the indications for ZYNRELEF. This sNDA is planned for late this year. Based on our agreement with the FDA sNDA2 should provide the basis for expanding the indication statement to cover essentially all 14 million target procedures.